An international hypertension study of more than 16,000 patients found that patients treated with three-year sustained blood pressure control with extended-release verapamil (COVERA-HS) or standard of care therapy (atenolol or hydrochlorothiazide) had similar incidences of heart attack, stroke and cardiovascular death.
Data from the CONVINCE (Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints) trial were presented on May 18 by primary principal investigator Dr. Henry Black, chairman, department of Preventive Medicine, Rush-Presbyterian-St. Luke's Medical Center, at the annual scientific session of the American Society of Hypertension (ASH) in New York.
Reporting the CONVINCE results, Dr. Black said, "We always believed that the size and scope of this study would result in confirmation of the hypothesis that all treatment regimens would provide a similar positive impact in preventing cardiovascular events. The standard of care arm has been shown in previous trials to provide benefit in reduction of cardiovascular events. CONVINCE confirmed that extended-release verapamil did as well."
The primary objective of CONVINCE was to examine whether a controlled-onset extended-release calcium channel blocker, COVERA-HS, could provide equivalent effects on the rate of heart attack, stroke and death as compared with standard of care therapy (the beta blocker atenolol or the diuretic hydrochlorothiazide).
The study enrolled 16,602 hypertensive patients with a second risk factor for cardiovascular disease (i.e., history of heart attack, stroke or smoking; type II diabetes; left ventricular hypertrophy; low HDL cholesterol; history of transient ischemic attack (TIA); body weight greater than 20% above ideal; atherosclerotic vascular disease; or presence of vascular bruit).
Patients were randomized to receive one of two study medications: either 180 mg/day of COVERA-HS or the physician directed choice of 12.5 mg/day of HCPage: 1 2 Related medicine news :1
Contact: John Pontarelli
Rush University Medical Center
. Lack of clinical trial participation may contribute to lower survival rates2
. Protecting children from industrial chemicals in the environment3
. Hopkins begins human trials with donor adult stem cells to repair muscle damaged from heart attack4
. US attempting to flout ethical practice for patient trials abroad5
. NIAID initiates trial of experimental avian flu vaccine6
. African-American women with endometrial cancer have more aggressive cancer than Caucasian women7
. WISE study starts in Toulouse: 60 days of bed-rest for terrestrial female astronauts8
. Sharing clinical trial results with participants may be beneficial9
. Emergency clopidogrel could save thousands of lives46,000-patient heart attack trial results10
. New trials for counseling caregivers and patients with Alzheimers begin11
. EuroVacc 02 HIV vaccine trial begins in February 2005